The complex nature of the ocular drug delivery barrier presents a significant challenge to the
effective administration of drugs, resulting in poor therapeutic outcomes. To address this …

Allergic conjunctivitis is one of the most common external eye diseases and the prevalence
has been increasing. The mainstay of treatment is topical eye drops. However, low …

The present study aimed at the development and evaluation of tacrolimus gellan gum
nanoparticles (TGNPs) for the effective management of dry eye disease (DED) following …

Traditional eye drops are convenient to use; however, their effectiveness is limited by their
poor retention time and bioavailability in the eyes due to ocular barriers. Therefore …

Tofacitinib (TF) is a selective oral jakanib approved by the USFDA for the treatment of
rheumatoid arthritis (RA). To overcome the adverse effects of orally administered TF, topical …

To overcome problems associated with topical delivery of tacrolimus (TCS), a
thermoresponsive in situ gel system containing pluronic F127 (PL), and chitosan (CS) was …

Doxorubicin (DOX) is commonly used for the treatment of many types of cancers but its
cardiotoxicity, owing to free radical formation, limits its clinical use. Hesperidin (HES), a …

Tacrolimus has shown efficacy in eye inflammatory diseases. However, due to the drug
lability, its formulation into a stable ophthalmic product remains a challenge. Tacrolimus …

Tacrolimus, also known as FK506, is a first-line drug for the topical treatment of immune-
mediated inflammatory anterior ocular diseases (IIAODs). However, due to its limited water …

Dry eye disease (DED) is a highly prevalent ocular surface disease that affects life quality
and reduces productivity at work. The purpose of this study is to improve the efficacy of …